About VOR

Founded: 2015
Employees: 76
CEO: Jean-Paul Kress
WebsiteView website: www.vorbio.com

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Recent VOR News & Updates

Announcement • Sep 08

Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Vor Bio announced the completion of enrollment in UPSTREAM MG, its global Phase 3 registrational trial evaluating telitacicept for the treatment of generalized myasthenia gravis (gMG). Topline results from the 24-week primary endpoint remain expected in the first half of 2027. Vor Bio also plans to initiate UPSTREAM oMG, a global Phase 3 registrational trial evaluating telitacicept for the treatment of patients with ocular myasthenia gravis, with the first patient dosing anticipated in the first half of 2027. The program is being advanced as a registrational expansion of Vor Bio’s existing MG development program, supporting potential future label expansion across the myasthenia gravis spectrum and builds on the broader clinical experience with telitacicept in MG, including RemeGen’s ongoing Phase 3 trial in oMG in China.UPSTREAM MG is a global, randomized, double-blind, placebo-controlled Phase 3 registrational trial evaluating the efficacy and safety of telitacicept in adults with gMG. The trial includes a 24-week placebo-controlled period followed by a 48-week open-label extension designed to evaluate the longer-term efficacy and safety of telitacicept. The primary endpoint is change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at Week 24. Key secondary endpoints include measures of muscle strength, clinical response and patient-reported outcomes. The global program builds on the Phase 3 trial of telitacicept conducted by RemeGen in China, in which telitacicept demonstrated statistically significant and clinically meaningful improvements in MG-ADL and Quantitative Myasthenia Gravis (QMG) scores at Week 24. In the subsequent open-label extension, clinical improvement continued through Week 48.

Recent updates

No updates

Vor Biopharma Inc. Stock Price

VOR Share Price Performance

VOR Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Vor Biopharma Inc. Key Details

About VOR

Recent VOR News & Updates

Vor Biopharma: A Funded Replication Story With Franchise Potential

Vor Biopharma Completes Phase 3 Myasthenia Trial and Unveils Ocular Disease Expansion

Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Recent updates

Vor Biopharma Inc. Competitors

Ionis Pharmaceuticals

Belite Bio

Rhythm Pharmaceuticals

CG Oncology